4503 On Other Exchanges
Symbol
Exchange
4503 is not on other exchanges.

astellas pharma inc (4503) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, oncology, immunology, nephrology, neuroscience, muscle diseases, and ophthalmology. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Vesicare, a treatment for overactive bladder; Protopic, a treatment for atopic dermatitis in the topical immunomodulator class; Harnal, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The company also offers Geninax, an oral new-type quinolone antibacterial agent; Celecox, a COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment for hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, a 5-HT3 receptor antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, it provides Lexiscan, a pharmacologic stress agent; Adenoscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. The company has a collaboration with Chromocell Corporation to develop and commercialize treatments for neuropathic pain and other pain conditions; and collaborative research agreement with the National Institute of Advanced Industrial Science and Technology to discover anti-protozoan parasite drugs for the treatment of Chagas' disease. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

17,217 Employees
Last Reported Date: 06/20/16
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥216.0M
Chief Administrative Officer, Chief Complianc...
Total Annual Compensation: ¥108.0M
Compensation as of Fiscal Year 2016.

astellas pharma inc (4503) Key Developments

Lupin Reportedly In Talks To Acquire Medicine Brands From Astellas And Shionogi

Lupin Limited (BSE:500257) is in talks to buy the off-patent medicine brands from Astellas Pharma, Inc. (TSE:4503) and Shionogi & Co., Ltd. (TSE:4507) which have been on the block, two people aware of the development said. The basket of drugs could fetch each company about $100 million, the two senior industry executives cited earlier said. A query sent by ET to Lupin's spokesperson remained unanswered till the time of going to press. Shionogi could not be contacted. Astellas declined to comment on the development.

Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan

Astellas Pharma Inc. and FibroGen, Inc. announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat (development code: ASP1517/FG-4592) for treatment of anemia in chronic kidney disease (CKD), which triggered a $10 million milestone payment from Astellas to FibroGen. The initiation of Phase 3 studies in Japan follows the positive results from two Phase 2 studies in Japan of roxadustat in CKD patients on dialysis and in CKD patients not on dialysis. In the Phase 2 studies in Japan of CKD patients receiving dialysis and not receiving dialysis, roxadustat was well tolerated and met the primary objective of demonstrating dose-related rates of hemoglobin (Hb) increase measured over the first six weeks of treatment, as well as anemia correction and Hb maintenance over the 24-week treatment period. The Phase 2 study in Japan of CKD patients not on dialysis was a multi-center, randomized, parallel-group, placebo-controlled, double-blind study over 24 weeks. The subjects, 107 CKD patients not yet receiving dialysis, were randomized to one of three roxadustat treatment arms (50 mg, 70 mg, 100 mg) or to a placebo arm, with roxadustat orally administered three times weekly (TIW) for the first six weeks of the study to evaluate dose response of efficacy and safety. This was followed by dose titration every four weeks until hemoglobin response was achieved, at which point hemoglobin was maintained with patients randomized to one of two dosing regimens (continuation of TIW dosing or a change to weekly (QW) dosing).

Astellas Promotes John Demaree to Vice President of Oncology Marketing in Americas Region

Astellas announced that John Demaree has been promoted to vice president, Oncology Marketing, Astellas Americas. In this role, Demaree will lead Astellas' oncology marketing team in promotion of in-market products, preparation for new oncology product launches and strategic planning and collaboration with the company's partner organizations in the Americas region. He will report to Mark Reisenauer, senior vice president, Oncology Business Unit, Astellas Americas. Demaree has over 25 years of experience working in the pharmaceutical industry, with over 20 years in oncology. Prior to his promotion, Demaree served as executive director, Oncology Marketing, where he helped execute the launch of XTANDI and promotion of Tarceva. Before joining Astellas, he worked at Abbott as the general manager for oncology business development and alliance management. Demaree also held roles of increasing responsibility at Novartis and Eli Lilly and Company.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4503.
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 20.1x
Price/Sales 2.8x
Price/Book 3.0x
Price/Cash Flow 16.4x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.